Carta al Director
Análisis del DRCR Network sobre coste-efectividad de aflibercept, bevacizumab y ranibizumab para el tratamiento de edema macular diabético y su aplicación en España
The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain
A. Navarro-Navarroa,
, D. Saloma, J.J. Martínez-Toldosb, P. Udaondoc, C. Fernández-Martínezb, L. Gutiérrez-Ariasa, A. Hervása, R. Rodrigod
Autor para correspondencia
a Servicio de Oftalmología, Hospital de Manises, Manises, Valencia, España
b Servicio de Oftalmología, Hospital General Universitario de Elche, Elche, Alicante, España
c Servicio de Oftalmología, Hospital Universitario La Fe, Valencia, España
d Grupo de Biomedicina Molecular, Celular y Genómica, Instituto de Investigación Sanitaria La Fe, Valencia, España
Leído
915
Vecesse ha leído el artículo
790
Total PDF
125
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 8 | 8 |
| 2025 11 | 0 | 22 | 22 |
| 2025 10 | 0 | 17 | 17 |
| 2025 9 | 0 | 9 | 9 |
| 2025 8 | 0 | 10 | 10 |
| 2025 7 | 0 | 16 | 16 |
| 2025 6 | 0 | 17 | 17 |
| 2025 5 | 0 | 13 | 13 |
| 2025 4 | 0 | 19 | 19 |
| 2025 3 | 0 | 13 | 13 |
| 2025 2 | 0 | 9 | 9 |
| 2025 1 | 0 | 16 | 16 |
| 2024 12 | 0 | 12 | 12 |
| 2024 11 | 0 | 11 | 11 |
| 2024 10 | 0 | 25 | 25 |
| 2024 9 | 0 | 9 | 9 |
| 2024 8 | 0 | 6 | 6 |
| 2024 7 | 0 | 7 | 7 |
| 2024 6 | 0 | 7 | 7 |
| 2024 5 | 0 | 6 | 6 |
| 2024 4 | 0 | 3 | 3 |
| 2024 3 | 0 | 26 | 26 |
| 2024 2 | 0 | 30 | 30 |
| 2024 1 | 0 | 17 | 17 |
| 2023 12 | 0 | 23 | 23 |
| 2023 11 | 0 | 39 | 39 |
| 2023 10 | 0 | 37 | 37 |
| 2023 9 | 0 | 4 | 4 |
| 2023 8 | 0 | 8 | 8 |
| 2023 7 | 0 | 10 | 10 |
| 2023 6 | 0 | 7 | 7 |
| 2023 5 | 0 | 10 | 10 |
| 2023 3 | 3 | 10 | 13 |
| 2023 2 | 0 | 1 | 1 |
| 2022 1 | 0 | 2 | 2 |
| 2022 12 | 0 | 3 | 3 |
| 2022 11 | 0 | 5 | 5 |
| 2022 10 | 0 | 7 | 7 |
| 2022 9 | 0 | 8 | 8 |
| 2022 8 | 0 | 6 | 6 |
| 2022 7 | 0 | 6 | 6 |
| 2022 6 | 0 | 5 | 5 |
| 2022 5 | 0 | 15 | 15 |
| 2022 4 | 0 | 20 | 20 |
| 2022 3 | 0 | 8 | 8 |
| 2022 2 | 0 | 2 | 2 |
| 2021 1 | 0 | 2 | 2 |
| 2021 12 | 0 | 3 | 3 |
| 2021 11 | 0 | 1 | 1 |
| 2021 10 | 0 | 2 | 2 |
| 2021 9 | 0 | 2 | 2 |
| 2021 8 | 0 | 2 | 2 |
| 2021 7 | 0 | 2 | 2 |
| 2021 6 | 0 | 2 | 2 |
| 2021 4 | 0 | 9 | 9 |
| 2021 3 | 0 | 3 | 3 |
| 2021 2 | 0 | 3 | 3 |
| 2020 1 | 0 | 1 | 1 |
| 2020 12 | 0 | 1 | 1 |
| 2020 11 | 0 | 3 | 3 |
| 2020 9 | 0 | 2 | 2 |
| 2020 8 | 0 | 4 | 4 |
| 2020 7 | 0 | 3 | 3 |
| 2020 6 | 0 | 4 | 4 |
| 2020 5 | 0 | 4 | 4 |
| 2020 4 | 0 | 2 | 2 |
| 2020 3 | 0 | 6 | 6 |
| 2020 2 | 0 | 2 | 2 |
| 2020 1 | 0 | 11 | 11 |
| 2019 12 | 0 | 16 | 16 |
| 2019 11 | 0 | 1 | 1 |
| 2019 10 | 0 | 9 | 9 |
| 2019 9 | 0 | 3 | 3 |
| 2019 8 | 0 | 7 | 7 |
| 2019 7 | 1 | 7 | 8 |
| 2019 6 | 0 | 15 | 15 |
| 2019 5 | 0 | 31 | 31 |
| 2019 4 | 0 | 10 | 10 |
| 2019 3 | 0 | 5 | 5 |
| 2019 2 | 0 | 4 | 4 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 4 | 4 |
| 2018 11 | 0 | 7 | 7 |
| 2018 10 | 0 | 19 | 19 |
| 2018 5 | 1 | 0 | 1 |
| 2018 3 | 5 | 0 | 5 |
| 2018 2 | 29 | 2 | 31 |
| 2018 1 | 14 | 1 | 15 |
| 2017 12 | 37 | 3 | 40 |
| 2017 11 | 11 | 3 | 14 |
| 2017 10 | 3 | 0 | 3 |
| 2017 8 | 3 | 0 | 3 |
| 2017 7 | 2 | 0 | 2 |
| 2017 6 | 1 | 0 | 1 |
| 2017 5 | 15 | 0 | 15 |
| 2017 4 | 0 | 1 | 1 |
| 2017 2 | 0 | 3 | 3 |
Mostrar todo
